Decibel Therapeutics, Inc. (DBTX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Decibel Therapeutics, Inc. (DBTX) trades at $4.91 with AI Score 44/100 (Grade C). Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for hearing and balance disorders. Market cap: $123.37M, Sector: Healthcare.
Last analyzed: Mar 15, 2026Analyst Coverage for DBTX: DBTX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DBTX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
DBTX: the 1 perspectives are evenly split.
Decibel Therapeutics, Inc. (DBTX) Healthcare & Pipeline Overview
Decibel Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in gene therapies for hearing and balance disorders. Their focus on congenital hearing loss and cisplatin-induced hearing loss, coupled with a collaboration with Regeneron, positions them in the competitive biotechnology landscape targeting unmet needs in audiology.
What Is the Investment Thesis for DBTX?
Decibel Therapeutics presents a focused investment opportunity within the biotechnology sector, targeting the underserved market of hearing and balance disorders. The company's lead asset, DB-OTO, addresses a significant unmet need in individuals with otoferlin-related hearing loss. Successful clinical trials and eventual commercialization of DB-OTO could drive substantial revenue growth. The collaboration with Regeneron Pharmaceuticals provides validation and resources, de-risking the development process. However, the inherent risks of clinical-stage biotechnology, including regulatory hurdles and clinical trial outcomes, must be considered. The company's P/E ratio of -1.95 reflects its current lack of profitability, typical for companies at this stage. Continued progress in clinical trials and strategic partnerships will be crucial for long-term value creation.
Based on FMP financials and quantitative analysis
DBTX Key Highlights
- Market capitalization of $0.12 billion indicates the company's current valuation in the biotechnology market.
- A negative P/E ratio of -1.95 reflects the company's current lack of profitability due to ongoing research and development expenses.
- Beta of -0.40 suggests a lower volatility compared to the overall market, potentially offering some downside protection.
- Strategic collaboration with Regeneron Pharmaceuticals provides access to resources and expertise, enhancing the development and commercialization prospects of gene therapies.
- Focus on gene therapies for congenital hearing loss addresses a significant unmet medical need, offering potential for substantial market penetration upon successful product approval.
Who Are DBTX's Competitors?
DBTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATYR aTyr Pharma, Inc. | $0.45 | -5.05% | $44.26M | 44 |
| GRAY Graybug Vision, Inc. | $5.50 | -10.80% | $120.98M | 44 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $98.95M | 71 |
| KNTE Kinnate Biopharma Inc. | $2.65 | -0.38% | $124.99M | 45 |
| NGM NGM Biopharmaceuticals | $1.54 | -1.28% | $128.53M | 49 |
| ANAB AnaptysBio, Inc. | $56.07 | +3.37% | 3B | 79 |
| SNDX Syndax Pharmaceuticals, Inc. | $18.25 | +1.90% | 2B | 79 |
| CGEN Compugen Ltd. | $2.02 | -0.98% | $191.00M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DBTX's Key Strengths?
- Proprietary gene therapy platform targeting hearing and balance disorders.
- Strategic collaboration with Regeneron Pharmaceuticals.
- Focus on underserved market with significant unmet medical need.
- Strong intellectual property portfolio.
What Are DBTX's Weaknesses?
- Clinical-stage company with no currently marketed products.
- High research and development costs.
- Reliance on successful clinical trial outcomes.
- Negative P/E ratio indicating current lack of profitability.
What Could Drive DBTX Stock Higher?
- DB-OTO Phase 1/2 clinical trial data readout in late 2026 will be a major catalyst.
- Advancement of DB-020 Phase 1b clinical trial for cisplatin-induced hearing loss.
- Continued strategic collaboration with Regeneron Pharmaceuticals for gene therapy development.
- Initiation of clinical trials for AAV.103 and AAV.104 in 2027.
What Are the Key Risks for DBTX?
- Unsuccessful clinical trial outcomes for DB-OTO and other pipeline programs.
- Regulatory delays or rejection of product candidates by the FDA.
- Competition from other biotechnology and pharmaceutical companies in the hearing loss market.
- Product liability claims related to gene therapy products.
- High research and development costs impacting profitability.
What Are the Growth Opportunities for DBTX?
- DB-OTO Clinical Development: The successful development and commercialization of DB-OTO, a gene therapy for otoferlin-related hearing loss, represents a significant growth opportunity. The addressable market includes individuals with profound hearing loss due to mutations in the otoferlin gene, a substantial unmet medical need. Positive Phase 1/2 clinical trial data could lead to accelerated regulatory approval and market entry by 2028, potentially generating significant revenue. The company's focus on this specific genetic mutation allows for a targeted and efficient development strategy.
- DB-ATO and AAV.201 for Bilateral Vestibulopathy: The development of DB-ATO and AAV.201, gene therapies aimed at restoring balance in patients with bilateral vestibulopathy, presents another growth avenue. Bilateral vestibulopathy affects a significant portion of the population, leading to impaired balance and quality of life. Successful regeneration of hair cells within the vestibule could provide a transformative treatment option. Clinical trials are expected to advance in the next 2-3 years, with potential market entry by 2029, pending regulatory approval. This program diversifies Decibel's pipeline and expands its target market.
- DB-020 for Cisplatin-Induced Hearing Loss: Decibel's DB-020, currently in Phase 1b clinical trial for the prevention of cisplatin-induced hearing loss, offers a growth opportunity in the otoprotection space. Cisplatin, a common chemotherapy drug, often causes irreversible hearing loss as a side effect. DB-020 aims to protect patients from this debilitating side effect, improving their quality of life during cancer treatment. Positive clinical trial results could lead to regulatory approval and market launch by 2027, capturing a share of the growing market for supportive cancer care. This program aligns with the trend towards personalized medicine and minimizing treatment-related side effects.
- AAV.103 and AAV.104 for GJB2 and STRC Deficiencies: The development of AAV.103 and AAV.104, gene therapies targeting hearing loss due to GJB2 and STRC deficiencies, respectively, expands Decibel's pipeline of gene therapies for congenital hearing loss. These programs address specific genetic mutations responsible for a significant proportion of inherited hearing loss cases. Preclinical studies are ongoing, with potential for clinical trials to commence in the next 3-4 years. Successful development and commercialization could lead to significant revenue generation and solidify Decibel's position as a leader in gene therapies for hearing disorders.
- Strategic Collaboration with Regeneron: The ongoing strategic collaboration with Regeneron Pharmaceuticals provides a significant growth opportunity for Decibel. Regeneron's expertise in gene therapy development, manufacturing, and commercialization enhances Decibel's capabilities and accelerates the development timeline for its gene therapy programs. The collaboration also provides access to funding and resources, de-risking the development process. Continued collaboration and expansion of the partnership could lead to further advancements in gene therapies for hearing loss and increased shareholder value.
What Opportunities Does DBTX Have?
- Successful development and commercialization of DB-OTO for otoferlin-related hearing loss.
- Expansion of pipeline with additional gene therapies for hearing and balance disorders.
- Potential for additional strategic collaborations and partnerships.
- Growing market for hearing loss treatments driven by aging population.
What Threats Does DBTX Face?
- Regulatory hurdles and potential delays in approval process.
- Competition from other biotechnology and pharmaceutical companies.
- Unsuccessful clinical trial outcomes.
- Potential for product liability claims.
What Are DBTX's Competitive Advantages?
- Proprietary gene therapy technology platform for treating hearing and balance disorders.
- Strong intellectual property portfolio protecting its product candidates and technologies.
- Strategic collaboration with Regeneron Pharmaceuticals provides access to resources and expertise.
- Focus on underserved market of hearing and balance disorders with significant unmet medical need.
What Does DBTX Do?
Decibel Therapeutics, Inc., founded in 2013 and headquartered in Boston, Massachusetts, is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders. Originally named Hearing Inc., the company rebranded to Decibel Therapeutics in April 2014, signaling a refined focus on addressing the complexities of auditory and vestibular system diseases. Decibel's research and development efforts are concentrated on three core areas: gene therapies for congenital, monogenic hearing loss; gene therapies for hair cell regeneration to address acquired hearing loss and balance disorders; and otoprotection therapeutics to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead product candidate, DB-OTO, is a gene therapy designed to restore hearing in individuals with profound hearing loss due to mutations in the otoferlin gene. Beyond DB-OTO, Decibel is developing DB-ATO and AAV.201, a gene therapy program aimed at restoring balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule. DB-020, another key asset, is in Phase 1b clinical trial for the prevention of cisplatin-induced hearing loss. Additional pipeline programs include AAV.103 for individuals with a gap junction beta-2 (GJB2) deficiency, AAV.104 for individuals with stereocilin (STRC) deficiency, and a cochlear hair cell regeneration program utilizing AAV-based gene therapy to convert supporting cells into outer hair cells. Decibel Therapeutics has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss, leveraging Regeneron's expertise in gene therapy development and commercialization. This collaboration underscores Decibel's commitment to advancing innovative therapies for patients with hearing and balance disorders.
What Products and Services Does DBTX Offer?
- Develop gene therapies for congenital, monogenic hearing loss.
- Create gene therapies for hair cell regeneration to address acquired hearing loss and balance disorders.
- Develop otoprotection therapeutics to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin.
- Focus on restoring functional cells within the cochlea to address hearing disorders caused by single gene mutations.
- Work to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders.
- Develop DB-OTO, a gene therapy product candidate to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene.
- Develop DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule.
How Does DBTX Make Money?
- Develop and commercialize gene therapies for hearing and balance disorders.
- Generate revenue through strategic collaborations with pharmaceutical companies.
- Out-license intellectual property and technology to other companies.
- Secure funding through venture capital, public offerings, and grants.
What Industry Does DBTX Operate In?
Decibel Therapeutics operates within the biotechnology industry, specifically targeting the niche market of hearing and balance disorders. The industry is characterized by high research and development costs, lengthy regulatory approval processes, and significant competition. The market for hearing loss treatments is substantial and growing, driven by an aging population and increasing noise exposure. Decibel's focus on gene therapies differentiates it from competitors primarily offering hearing aids and cochlear implants. Companies like ATYR Pharma and Jounce Therapeutics also operate in the broader biotechnology space, but Decibel's specialization in audiology provides a distinct market position.
Who Are DBTX's Key Customers?
- Individuals with congenital hearing loss due to genetic mutations.
- Patients experiencing acquired hearing loss and balance disorders.
- Cancer patients undergoing chemotherapy with cisplatin.
- Healthcare providers and audiologists treating hearing and balance disorders.
DBTX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Decibel's long-term potential, indicating that key stakeholders believe in the company's prospects.
- Positive sentiment in online forums reflects optimism about upcoming clinical trials, which could validate their innovative therapies.
- The company's focus on addressing hearing loss has garnered increased interest, tapping into a niche market with significant unmet needs.
- Recent partnerships with research institutions enhance credibility and could accelerate product development, fostering a bullish outlook among investors.
Bear Case
- Concerns over the timeline for clinical trial results have led to increased skepticism among investors, creating a cautious market sentiment.
- Social media discussions show a notable number of bearish opinions, highlighting worries about regulatory hurdles that could delay product launches.
- Insider selling activity in the past month raises questions about the company's immediate outlook, potentially shaking investor confidence.
- Market perception remains cautious due to broader economic conditions affecting biotech stocks, leading to hesitance among potential investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
DBTX Latest News
-
The FDA Has Granted Fast Track Designation To Decibel Therapeutics' DB-OTO, The Company's Lead Gene Therapy Product Candidate For Congenital Hearing Loss Caused By Mutations Of The Otoferlin Gene
benzinga · Aug 25, 2023
-
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
benzinga · Aug 11, 2023
-
Decibel Therapeutics Q2 2023 Net Loss Of $18.15M Versus Loss Of $17.05M A Year Ago
benzinga · Aug 11, 2023
-
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
benzinga · Aug 10, 2023
DBTX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DBTX.
Price Targets
Wall Street price target analysis for DBTX.
DBTX MoonshotScore
What does this score mean?
The MoonshotScore rates DBTX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest News
The FDA Has Granted Fast Track Designation To Decibel Therapeutics' DB-OTO, The Company's Lead Gene Therapy Product Candidate For Congenital Hearing Loss Caused By Mutations Of The Otoferlin Gene
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Decibel Therapeutics Q2 2023 Net Loss Of $18.15M Versus Loss Of $17.05M A Year Ago
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Leadership: Laurence E. Reid
CEO
Laurence E. Reid serves as the Chief Executive Officer of Decibel Therapeutics. His career spans various leadership roles in the biotechnology and pharmaceutical industries. Prior to Decibel, he held executive positions at Alnylam Pharmaceuticals and Shire Pharmaceuticals. Reid's expertise lies in strategic planning, business development, and commercialization of novel therapies. He holds an MBA from Harvard Business School and a Ph.D. in Biology from MIT, providing him with a strong scientific and business foundation.
Track Record: Under Laurence Reid's leadership, Decibel Therapeutics has advanced its pipeline of gene therapies for hearing and balance disorders, including the lead program DB-OTO. He has overseen the strategic collaboration with Regeneron Pharmaceuticals and guided the company through key clinical milestones. His focus on innovation and strategic partnerships has positioned Decibel as a leader in the field of audiology therapeutics.
DBTX Healthcare Stock FAQ
What does Decibel Therapeutics, Inc. do?
Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing transformative treatments for hearing and balance disorders. Their approach centers on gene therapies and otoprotection therapeutics, targeting both congenital and acquired hearing loss. The company's lead product candidate, DB-OTO, aims to restore hearing in individuals with profound hearing loss due to mutations in the otoferlin gene. Decibel also has a strategic collaboration with Regeneron Pharmaceuticals to develop gene therapies for monogenic forms of congenital hearing loss, enhancing its research and development capabilities.
What are the main risks for DBTX?
Decibel Therapeutics faces several risks inherent to clinical-stage biotechnology companies. A primary risk is the potential for unsuccessful clinical trial outcomes, which could delay or halt the development of its product candidates. Regulatory hurdles and potential delays in the approval process also pose a significant risk. Competition from other biotechnology and pharmaceutical companies in the hearing loss market could impact market share and pricing. Product liability claims related to gene therapy products represent another potential risk. Additionally, the company's high research and development costs could impact its profitability and financial stability.
What are the key factors to evaluate for DBTX?
Decibel Therapeutics, Inc. (DBTX) holds an AI score of 44/100 (low). Not financial advice.
How frequently does DBTX data refresh on this page?
DBTX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DBTX's recent stock price performance?
Decibel Therapeutics, Inc. (DBTX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary gene therapy platform targeting hearing and balance disorders. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider DBTX overvalued or undervalued right now?
Valuing Decibel Therapeutics, Inc. (DBTX) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying DBTX?
Before investing in Decibel Therapeutics, Inc. (DBTX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding DBTX to a portfolio?
Key strength of Decibel Therapeutics, Inc. (DBTX): Proprietary gene therapy platform targeting hearing and balance disorders. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending for DBTX, therefore some sections may be incomplete.